WCG expands global clinical research support presence

PRINCETON, New Jersey, May 22, 2018 /PRNewswire/ — WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company’s new office in Tokyo, Japan. WCG’s expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials, particularly in the critical areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases.

“WCG’s Tokyo office will be home to our Clinical Services Division in Asia, as well as a center of excellence for our growing Patient Engagement Group,” said Donald A. Deieso, PhD, chairman and CEO of WCG. “By expanding WCG’s footprint abroad, we are helping to ensure that every trial— especially the most complicated and challenging ones—can benefit from our latest advances in trial optimization, signal detection and patient recruitment.”

WCG maintains an active presence in 65 countries around the world, helping research sponsors, contract research organizations (CROs) and investigative sites to work together more effectively to conduct faster, safer, and more predictable clinical trials.

In the past decade, Asia has become an increasingly attractive destination for clinical research, with a clinical trials infrastructure designed to foster speed, cost effectiveness and quality.  With a population of more than four billion people, Asia also provides research sponsors with access to a large number of patients for clinical trial recruitment.

About WCG (WIRB-Copernicus Group)
WCG (WIRB-Copernicus Group) is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry’s first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

Logo- https://mma.prnewswire.com/media/659075/WCG_Logo_Logo.jpg  

MILAN, May 22, 2018 /PRNewswire/ — Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Shanghai Pharmaceuticals Holding Co. Ltd., a leading pharmaceutical group in China – focused on providing innovative drugs in the field of oncology, infectious and cardiovascular diseases – have signed today a collaboration agreement on new R&D activities in China.

The collaboration is focused on the exploitation of the potentialities of the Bracco microbubbles technology platform, to support the development of innovative Shanghai Pharmaceuticals therapeutic drugs in the oncologic field.

Microbubbles have already changed medical imaging in Contrast Enhanced Ultrasound (CEUS) – a high-sensitivity, non-invasive, real-time, cost-effective and radiation-free modality that improves the visualization and assessment of cardiac cavities, large vessels and tissue vascularity – and are now also considered as a high potential platform for treatment monitoring in oncology.

“China represents the second largest market and one of the most relevant areas of development for Bracco” said Diana Bracco, President of the Bracco Group. “Since 2001 we have been directly present in China with a Joint Venture with Shanghai Sine (part of Shanghai Pharmaceuticals Ltd Group) that at the end of 2016 has been extended for additional 20 years, consolidating Bracco’s strategic presence in China.”

“China is a growing force in healthcare innovation and today we start a new phase for our shared commitment to deliver better patient care” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “The joint effort with Shanghai Pharmaceuticals further reinforces our long-term partnership in China, and provides additional opportunities to expand the use of the microbubbles in new fields by targeting tumor angiogenesis in a very effective and safe way: the combination of these innovative treatment monitoring capabilities from Bracco with a new immuno-oncology therapy by SPH will allow to address a very significant, unmet medical need in pancreatic cancer.”

Commenting on the announcement, Mr. Zhou Jun, Chairman and Non-executive Director at Shanghai Pharmaceuticals, concluded: “We are delighted to sign this agreement with Bracco. Shanghai Pharmaceuticals has a breadth of capabilities in R&D and today the strategic alliance in innovation will foster our partnership with a global leader in diagnostic imaging and its cutting-edge microbubbles platform in ultrasound.”

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.

Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through radioactive tracers. The diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology.

The Company operates in more than 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With an on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.

Operational investments have been made in order to achieve top quality and compliances with a sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.

Bracco Imaging is an innovative Research and Development (R&D) player with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centres located in Italy, Switzerland, and the USA.

To learn more about Bracco Imaging, visit www.braccoimaging.com.

About Shanghai Pharmaceuticals Holding Co., Ltd,

Shanghai Pharmaceuticals Holding Co. Ltd. (SPH) is ranked second in size among Chinese pharmaceutical companies (Forbes 2017 “Global 2000”). The company has a dual listing on the Shanghai and Hong Kong stock exchanges. SPH is involved in four major business areas: R&D, Manufacturing, Distribution and Retail.

SPH aims to provide both pharmaceutical products and healthcare services following international standards. SPH strives to improve the quality of products and manufacturing processes as well as delivery to customers. SPH is committed to providing innovative drugs to enhance public health in China and around the world.

SPH has established JVs and partnerships with prominent global companies to collaborate on R&D and manufacturing of innovative drugs and nutritional supplements. Through key M&A investments, SPH aims to build a global reputation in the pharmaceutical field.

For more information, please visit: www.sphchina.com.

Roberto Cattaneo
Bracco Imaging Media Relations
mediarelations.imaging@bracco.com 
+39-02-21771

Keping Wang
SPH Office Brand Manager
wangkp@sphchina.com 
+86 21 63730908-4052  

Logo – https://mma.prnewswire.com/media/327852/Bracco_Diagnostics_Logo.jpg

Source: Bracco Imaging S.p.A.

Source: WAT Medical Enterprise Ltd.

MAASTRICHT, Netherlands, May 22, 2018 /PRNewswire/ —

A highly innovative software, developed by Pie Medical Imaging – PMI – B.V. (Esaote Group) will be presented at EuroPCR 2018, the world-leading course in interventional cardiovascular medicine, held in Paris, Palais des Congrès (France) between 22 – 25 May 2018.

This software – called CAAS vFFR (Cardiovascular Angiographic Analysis Systems for vessel Fractional Flow Reserve) – can calculate the pressure drop and vFFR value in the coronary artery non-invasively, which means that there is no need for a pressure wire and hyperemic agent.

FFR is an established technique used in interventional cardiology to measure pressure differences across a coronary stenosis. Based on this, cardiologist may take a decision on whether a coronary stenosis has to be treated with angioplasty or not. This examination is done during a catheterization procedure with the support of costly pressure wire and hyperemic agent.

CAAS vFFR allows clinicians to use two standard angiograms taken during a standard catheterization procedure as input to get access to coronary physiology assessment. For percutaneous coronary interventions (PCI), within one easy workflow, CAAS vFFR offers a unique combination of functional and anatomical lesion assessment (such as percentage stenosis) to support the interventional cardiologist in the clinical decision making process.

FAST, a clinical study led by Ken Masdjedi, MD and Joost Daemen MD, PhD from Erasmus Medical Center, Rotterdam shows that vFFR as calculated using CAAS vFFR has a high linear correlation to invasively measured FFR.

“In the FAST study“ said Joost Daemen MD, PhD, principal investigator “we demonstrated that vFFR as calculated using CAAS vFFR has a high linear correlation to invasively measured FFR and high diagnostic accuracy to detect FFR ≤ 0.80. vFFR is a promising, fast and easy to use tool to assess coronary physiology without the need for a costly pressure wire or hyperemic agent.“

“We are very proud of this technological and clinical achievement” declared René Guillaume, PMI CEO “which is the result of 30-year commitment and experience of our Company in the field of cardiovascular analysis software and of the successful collaboration with the most prestigious medical and scientific research centers“.

CAAS vFFR received USA 510(k) market clearance and is CE marked and PMDA cleared (Japan). For more product information on CAAS vFFR: https://www.piemedicalimaging.com/product/caas-workstation/vffr/

About PMI
PMI BV is a world leader in quantitative analysis of cardiovascular images, well known for its CAAS and 3mensio product lines. Based in Maastricht (The Netherlands), it hosts the global sales for the CAAS and 3mensio product lines. PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector, in particular the areas of ultrasound, dedicated MRI and Medical IT. More information about PMI is available at http://www.piemedicalimaging.com

For further details please contact:
Ir. Tristan Slots
PMI T: +31-43-328-13-28
pmi@pie.nl

Mariangela Dellepiane
Esaote
+39-010-6547249
mob. +39-335-1289783
mariangela.dellepiane@esaote.com

GUANGZHOU, China, May 21, 2018 /PRNewswire/ — Recently, Infinitus (China) Company Ltd. (Infinitus (China)) has been accredited as 2017 National High-Tech Enterprise of China for three years since November 9, 2017. Infinitus (China) has been recognized as National High-Tech Enterprise for the fourth time along with its first accreditation in 2008.

Infinitus (China) Re-Accredited as a National High-Tech Enterprise

The affirmation work of National High-Tech Enterprises began in 1991 to promote scientific and technological progress and enhance enterprise innovation capabilities. Since 2008, National High-Tech Enterprises have been jointly accredited by the Ministry of Science and Technology of the P.R.C, the Ministry of Finance of the P.R.C, and the State Administration of Taxation. The accreditation is reviewed rigorously in four areas, which are: key intellectual property rights of enterprises, transformation capacity of scientific and technical payoffs, organizational management level of R&D, and growth index of sales and assets.

During the past nine years, Infinitus (China) has been recognized as “National High-Tech Enterprise” four times on the basis of emphasis and persistence on scientific research. The company has established a unique R&D system featured by multiple scientific research platforms and the whole industry chain which supports the development of exquisite products. It also owns a number of core independent intellectual property rights and leads in the research of compound polysaccharides technology.

Currently, Infinitus (China) cooperates closely with authoritative global research institutions and universities, including University of Cambridge, Stanford University, French National Centre for Scientific Research – Paris Diderot University and China Academy of Chinese Medical Sciences. Professor Jules A. Hoffmann, the 2011 Nobel Laureate for Physiology or Medicine, has been appointed as a scientific advisor of the company since 2017.

The national strategy of Healthy China boosts people’s demand for health and development of the health industry. Thereupon, consumers and regulators have proposed higher requirements for the quality of products, depending largely on the scientific research strength and innovation capacity of enterprises, which have become a footstone for enterprises to expand the market and beat the competition.

For this accreditation, Infinitus (China) said that it will continuously increase investment and improve its scientific research strength to develop and produce more high-quality Chinese herbal health products, further meet consumer needs and make a positive contribution to society.

About Infinitus (China) Company Ltd.

Infinitus (China) Company Ltd., founded in 1992 and headquartered in Guangzhou, is a member of LKK Health Products Group. The Company focuses on R&D, production, sales and services of Chinese herbal health products with over 4,700 employees.

Photo – https://photos.prnasia.com/prnh/20180518/2137541-1-a

HO CHI MINH CITY, Vietnam, May 21, 2018 /PRNewswire/ — According to a report from Nielsen Vietnam, Vietnam is leading the growth in the region with a rate of 6.7%, whilst other emerging markets have slowed down in FMCG in 2017. Vietnam is also one of the top destinations for business expansion, especially retailing. According to the Nielsen Future Business Sentiment Beauty Survey conducted in 2016, Vietnam was in Asia’s Top 3 priority markets for companies that are likely to expand. On the other hand, ATKearney Global Retail Development Index 2017 said Vietnam was amongst the Top 6 most attractive markets worldwide. As the middle class urbanises, they seek to experience premium brands and see more new players entering the Vietnamese beauty market, as local consumers are becoming more conscious of beauty treatment and products. With the rapid growth of digital marketing, Vietnam’s e-commerce is booming across categories, whilst the beauty sector is leading the trend and indeed, brand origin is in fact more important than choice, price, function and quality in Vietnam.

vietbeauty banner

According to Statista, revenue in the cosmetics and personal care market in Vietnam amounts to US$ 1,620 million in 2018. The market is expected to grow annually by 8.6% (CAGR 2018-2021). The market’s largest segment is skin care, with a market volume of US$ 595 million in 2018.

On 19-21 July 2018 at the Saigon Exhibition and Convention Center (SECC), Ho Chi Minh City, vietbeauty 2018 will feature a full range of Asian and European beauty products and services from companies representing Vietnam, the United States, Japan, Korea, Hong Kong, Thailand, Taiwan, Mainland China, Malaysia, Indonesia, the Philippines, Singapore, India, Australia, UAE, Poland, Switzerland, Bulgaria, Canada and France. Many of these brands will take the opportunity to launch new products and innovations during the event.

In addition, vietbeauty will host different conferences covering market trends. Hosted by Nielsen Vietnam, there will be a conference focusing on the topic “What’s Next in Beauty?” and panel discussion on beauty care and aesthetics field. Other highlights in the event include continuous live demonstrations on hair, nails, and make-up applications and techniques together, with many interesting experimental activities during the show.

The show will also feature Cosme Zone and Derma Zone for the first time in Vietnam, showing new and unique products for visitors to experience across the region.

The event is expected to attract over 250 exhibiting brands when it opens its doors in July 2018. Visitors are welcome to pre-register today at www.vietbeautyshow.com or contact the organiser directly by phone at (84)–28–3622–2588 (extension 153) or email at vietbeauty@ubm.com. 

For further information, visit www.vietbeautyshow.com

Online visiting pre-registration now opens: https://www.ubmonlinereg.com/registration/default.aspx?fid=807&lang=en

Notes to editors:

ABOUT UBM ASIA LTD

www.ubm.com/asia   

Owned by UBM plc listed on the London Stock Exchange, UBM Asia is the largest events organiser in Asia, India and SE Asia. We are also the leading commercial organiser in China. Established with its headquarters in Hong Kong and subsidiary companies across Asia and in the US, UBM Asia has a strong global presence in 25 major cities with 31 offices and over 1,600 employee.

With a track record spanning over 30 years, UBM Asia operates in 11 market sectors with over 290 events, 28 targeted trade publications, 18 round-the-clock online products for over 2,000,000 quality exhibitors, visitors, conference delegates, advertisers and subscribers from all over the world. We provide a one-stop diversified global service for high-value business matching, quality market news and online trading networks.

Media contact:

Ms Susan Nguyen
P: +84-28-3622-2588 (Extension 153)
nga.nguyen@ubm.com

Photo – https://photos.prnasia.com/prnh/20180517/2136304-1
Logo – http://photos.prnasia.com/prnh/20170222/8521701055LOGO

OXFORD, England and LA CIOTAT, France, May 17, 2018 /PRNewswire/ — e-STROKE SUITE is the complete decision support software for the assessment of CT and MR scans of ischemic stroke patients 

Brainomix, based in Oxford, UK and Olea Medical, based in La Ciotat, France have joined forces to launch the e-STROKE SUITE. e-STROKE SUITE is the most complete imaging solution for stroke, which will transform how imaging is used in the field. It is the most holistic imaging solution available anywhere for clinical use, and integrates Artificial Intelligence (AI) algorithms, proprietary Bayesian post-processing methods and big data to support the assessment of plain CT, CT Angiography (CTA) and CT/MR perfusion scans.

Core components of the e-STROKE SUITE include e-ASPECTS and Olea Sphere® which are medical imaging solutions developed by the two companies that are already in use in hospitals around the world. The e-STROKE SUITE offering also includes the e-CTA software solution recently launched by Brainomix.

Brainomix started as a spin-off from the University of Oxford in 2010 and has evolved into a world-leading, AI-based medical imaging software company dedicated to improving outcomes of patients with neurological and cerebrovascular disorders. Brainomix’s clinically validated and proprietary software solutions are used in routine clinical practice at leading stroke centers in more than 16 countries worldwide with plans to expand further during 2018.  

Olea Medical has established a strong credibility in stroke management, through the introduction of cutting-edge technologies, and partnerships with leading institutions worldwide. With over 100 scientific publications on their technology applied to stroke management in clinical practice in over 300 of the most prestigious healthcare centers worldwide, Olea Medical is the recognized leader in standardized, vendor-neutral, advanced quantitative and qualitative image post-processing.

Dr. Michalis Papadakis, Brainomix CEO, stated: “Today we announce to the stroke community what we believe to be a significant milestone for stroke imaging. What brings the two companies together is a common vision of improving lives of stroke patients by providing state-of-the-art imaging technology. Our new e-STROKE SUITE acts as a standardized and fast decision support tool to help physicians choose an appropriate treatment based on the quantitative analysis of plain CT, CTA and CT/MR perfusion scans.”

“Ten years ago, Olea was created with one main mission: improve diagnosis for life,” said Fayçal Djeridane, Olea Medical CEO. “Stroke was, at that time, our main concern. It is now one of our major priorities. Today, along with our innovative approach in advanced post-processing, we are happy to join forces with Brainomix to offer doctors the most outstanding technologies for the utmost benefit of patients all over the world. I trust this partnership will make a significant difference in patient care and bring new hope to those who struggle with this severe condition.”

Professor Istvan Szikora, Interventional Neuroradiologist at the National Institute of Neurosciences in Hungary stated, “Clinical practice in stroke requires a single imaging workflow that can speed up and standardize interpretation of CT, CTA and CT/MR perfusion scans to assist  fast and accurate decision making. It is essential that imaging software solutions can support this workflow and are applied not only in the comprehensive stroke centres but also in the whole network of referring hospitals. Such solutions should come under a single software package and we are therefore watching with great enthusiasm and optimism the joint effort of Brainomix and Olea Medical, two leading companies in the field of medical imaging software for stroke, to launch the e-STROKE SUITE.”

About Brainomix:

Brainomix, a medical diagnostics software company, was founded in 2010 as a spin-out from the University of Oxford and is dedicated to improving outcomes for patients with neurological and cerebrovascular disorders. Brainomix is currently focusing on acute stroke. By developing and equipping physicians with world-class, artificial intelligence-based medical imaging software, Brainomix aims to help them in making life-saving treatment decisions by supporting the selection of the right treatment for the right stroke patient.

For more information, please visit http://www.brainomix.com

About Olea:

Olea Medical®, a Canon Medical Systems Corporation company, is a provider of advanced MR and CT imaging post-processing solutions. Based in La Ciotat, France, it designs and markets Olea Sphere®, a suite of innovative medical imaging applications that significantly improve diagnosis and monitoring. The company has built up its credibility through the domestication of cutting-edge technology, and partnerships with leading institutions worldwide. With proprietary Bayesian algorithms and optimization methods applied to medical imaging, Olea Medical® is today a key player in standardized, vendor-neutral, advanced MR quantitative and qualitative image post-processing. Covering both morphologic and functional imaging, Olea Medical® post-processing solutions bring complex mathematics into clinical practice for easy access to accurate and robust biomarkers and for enhanced diagnostic confidence and response-to-treatment assessment.

For more information, please visit http://www.olea-medical.com

SHENZHEN, China, May 20, 2018 /PRNewswire/ —

Social E-commerce A New Business Model

Social e-commerce is a derivative e-commerce mode. It is based on interpersonal relationship networks, with the help of a social media propagation path like WeChat, which is the most popular social app in China, through social interaction and user generated content to assist selling and consumption. It is the integration of e-commerce and social media.

In May 2018 the Yibaifen Group visited University of Florence in Italy. They discussed the development of brand in China and Europe and the cultural diversity.

As a new business model, social e-commerce in China is rising rapidly. It has gradually changed the way people consume and promote new products. Social e-commerce employed 20 million people in 2017. Since 2015, the mobile social e-commerce scale has exceeded 100 billion RMB. It is predicted that the market scale will reach 370 billion RMB by 2020.

Yibaifen Standing Out

Yibaifen Group is a health industry company integrating R&D production and sales based on social e-commerce. Yibaifen is leading the new retail of China’s health industry. The founder CEO Mr. Chen Hangzhou and his founding team have rich career experience in internet industry. They strive to provide a green and healthy lifestyle for mankind and provide an efficient and open platform for customers.

With an accurate marketing model and mature advertising strategy, Yibaifen has had rapid expansion through social e-commerce retail. Yibaifen has more than 60,000 agents and 200 offline retail stores. Products such as Prebiotics Tiantianai and Xiaohuayang sell well in China, USA, UK, Mexico and other international markets.

Bonuses for Yibaifen Agents

Yibaifen has put the interest of distributors and agents first. In the past 2 years, Yibaifen has rewarded its agents with world travel to Bali island and Taiwan. In May 2018, a customized tour of France, Italy and Switzerland for 9 days will be rewarded to the top agents.

Photo – https://photos.prnasia.com/prnh/20180519/2132079-1

FORT WASHINGTON, Pennsylvania, May 17, 2018 /PRNewswire/ — The National Comprehensive Cancer Network^® (NCCN^®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer; a newly-created position for the nonprofit alliance of top U.S. cancer centers. Dr. Koh will add additional physician representation at NCCN headquarters, which includes Chief Executive Officer Robert W. Carlson, MD, a practicing oncologist and internationally-recognized breast cancer expert. Dr. Koh is a board-certified radiation oncologist, professor, and medical director for radiation oncology at Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance – an NCCN Member Institution. He specializes in the treatment of gynecologic and gastrointestinal malignancies.

The new CMO role will include overseeing the NCCN Oncology Research Program (ORP), which strives to improve and prolong the lives of people with cancer by advancing collaborative research. Dr. Koh will also help oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) program. In addition, he will be responsible for medical leadership and oversight for NCCN’s continuing medical education program, and will represent the organization at clinical and scientific meetings.

“Wui-Jin has an extensive history of strong contributions to NCCN, and to the entire oncology community, patients and providers,” said Dr. Carlson. “This is someone who has already represented our organization worldwide, most-recently in Kenya, Uganda, and Trinidad. He has devoted his entire career to improving outcomes for people with cancer. That makes him an ideal representative for NCCN’s mission.”

“Studies have repeatedly shown how adhering to NCCN Guidelines^® leads to better outcomes for people with cancer; it’s been a privilege to contribute to that life-saving legacy,” said Dr. Koh. “I look forward to doing even more in this new role to make sure that everyone has access to the best possible cancer care, worldwide.”

Dr. Koh began contributing his time to NCCN as a founding member of the NCCN Guidelines Panel for Uterine/Cervical Cancer in 1997, helping clinicians stay up-to-date on evidence-based treatment standards. He was named panel co-chair in 2004. His work is an integral part of the ongoing creation of the NCCN Harmonized Guidelines^™ for Sub-Saharan Africa. Dr. Koh also served as a member of the pancreatic cancer panel for seven years, and currently sits on the editorial board of JNCCN – Journal of the National Comprehensive Cancer Network. He is also an editorial board member for Cancer, American Journal of Clinical Oncology, and Gynecologic Oncology Research and Practice, and a former member for Gynecologic Oncology.

In 2017, Dr. Koh was honored with the NCCN Board of Producer’s Award for individuals who exceeded expectations and provided exemplary service – alongside his longtime colleague, the late Benjamin Greer, MD. Outside of NCCN, Dr. Koh has held leadership positions with NRG Oncology (formerly Gynecologic Oncology Group), Western Association of Gynecologic Oncologists, International Society of Gynecologic Cancer, the National Cancer Institute’s Gynecologic Cancer Steering Committee, and the Society of Gynecologic Oncology.

“Looking beyond the lengthy list of impressive credentials, Wui-Jin is simply a great guy, and a wonderful communicator,” said Dr. Carlson. “He interacts well with people one-on-one and in groups. I look forward to him playing an integral role in improving the quality, effectiveness, and efficiency of cancer care at NCCN.”

Dr. Koh’s official start date will be October 1, 2018. Click here to download a high-resolution headshot.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network^® (NCCN^®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana–Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

Logo – https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg

Source: Canary Medical Inc.